国际肿瘤学杂志

国际肿瘤学杂志 ›› 2014, Vol. 41 ›› Issue (8): 712-714.doi: 10.3760/cma.j.issn.1673-422X.2014.09.020

• 论著 • 上一篇    下一篇

弥漫性大B细胞淋巴瘤中MYC/BCL2蛋白 共表达及其意义分析

方建晨,李征,夏朝霞,张慧芝   

  1. 315020 宁波市临床病理诊断中心病理科（方建晨、张慧芝），技术室（李征、夏朝霞）
  • 出版日期:2014-09-25 发布日期:2014-09-05
  • 通讯作者: 方建晨 E-mail:jianchenfangt@sina.com
  • 基金资助:

    宁波市自然科学基金（2012A610200）

Expression and significance of MYC/BCL2 protein coexpression in diffuse large B-cell lymphoma

Fang Jianchen, Li Zheng, Xia Zhaoxia, Zhang Huizhi   

  1. Department of Pathology, Ningbo Clinical Pathological Diagnosis Center, Ningbo 315020, China
  • Online:2014-09-25 Published:2014-09-05
  • Contact: Fang Jianchen E-mail:jianchenfangt@sina.com

PDF

1945

摘要： 目的探讨245例弥漫性大B细胞淋巴瘤（DLBCL）中MYC/BCL2蛋白共表达状况及其与生发中心细胞样(GCB)及nonGCB亚型是否存在相关性。方法使用免疫组织化学方法对DLBCL石蜡标本制作的组织芯片进行MYC、BCL2、CD10、BCL6、MUM1、KI67检测，并对蛋白表达状况进行统计分析。结果245例DLBCL标本中，nonGCB患者163例（66.5%），GCB患者82例（33.5%），MYC和BCL2双阳性患者88例，占患者总数的35.9%（88/245），占nonGCB病例的 41.7%（68/163)，占GCB病例的24.4%（20/82)，在这两种亚型表达的差异具有统计学意义（χ2=7.116，P=0.008）。结论DLBCL中MYC/BCL2蛋白共表达在nonGCB亚型比GCB亚型更多，可以按照MYC/BCL2的共表达情况，把DLBCL分成不同亚群以区别治疗和判断预后。

关键词: 淋巴瘤, 大B细胞, 弥漫性, 原癌基因蛋白质c-myc, BCL2蛋白

Abstract: ObjectiveTo explore the condition of MYC/BCL2 protein coexpression in 245 patients with diffuse large Bcell lymphoma (DLBCL) and to find the correlations among MYC/BCL2 protein coexpression, the germinal center Bcelllike (GCB) subtype and nonGCB subtype. MethodsParaffinembedded lymphoma samples from 245 patients with DLBCL were studied using immunohistochemistry for MYC, BCL2, CD10, BCL6, MUM1 and KI67. And the protein expressions of them were analyzed. ResultsIn the specimens of 245 patients with DLBCL, the patients with nonGCB were 163 (66.5%), and the patients with GCB were 82 (33.5%). The group of MYC/BCL2 protein coexpression comprised 35.9% (88/246) of the all patients. NonGCB subtype group had a significantly higher frequency of MYC/BCL2 protein coexpression than the GCB subtype group (41.7%∶24.4%; χ2=7.116, P=0.008). ConclusionThe data shows that MYC/BCL2 protein coexpression occurs significantly more commonly in the nonGCB subtype. We can predict prognosis and choose therapeutic regimen base on the assessment for MYC and BCL2 protein expression.

Key words: Lymphoma, large B-cell, diffuse, Proto-oncogene proteins c-myc, BCL2 protein